-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 16, Saisheng Pharmaceuticals announced that it has reached a cooperation and licensing agreement with Tarveda Therapeutics, and will serve as the latter's exclusive partner in the development, production and commercialization of the Greater China region (including Mainland China, Hong Kong, Macau and Taiwan) New product portfolio of small molecule conjugated drugs
.
The product portfolio consists of a combination of PI3K inhibitors and HSP90, and is currently in the preclinical research stage
According to the agreement, Saisheng Pharmaceutical will pay a down payment to Tarveda and have the right to make equity investments in the latter
.
Tarveda will be eligible to receive milestone payments from Saisheng Pharmaceutical for key stages of development, approval and commercial sales, as well as royalties based on the net sales of the licensed product portfolio in Greater China
The phosphatidylinositol-3-kinase (PI3K) pathway is involved in cell growth, survival and metabolism, and its abnormal activation occurs in different solid tumors and blood cancers, including all subtypes of indolent non-Hodgkin's lymphoma
.
The linker and heat shock protein 90 (HSP90) is a molecular chaperone protein that can be highly activated in the harsh tumor environment of various solid tumors and cancers, but it is still in a relatively dormant state in normal tissues
According to the press release, the product portfolio introduced by Saisheng Pharmaceutical will selectively deliver payload pan-PI3K inhibitors to solid tumors by combining with activated HSP90.
The linker masks the activity of pan-PI3K inhibitors.
Until it is preferentially released in the tumor, thereby further enhancing the tolerance of the payload
.
Previously, Tarveda has published data from a preclinical study showing that this product combination has rapid and sustained tumor accumulation of conjugates, deep pathway inhibition, and efficacy potential superior to PI3K inhibitors themselves
.
This shows that the product portfolio has formed a set of tumor-targeted drug delivery mechanisms that can deliver payloads directly to tumors
It is worth mentioning that this is not the first cooperation between Saisheng Pharmaceutical and Tarveda
.
In March 2020, Saisheng Pharmaceutical introduced the latter's rights to jointly develop and commercialize a micro-drug conjugate, PEN-866, in the Greater China region
Reference materials:
Reference materials:[1] Saisheng Pharmaceutical and Tarveda reached an exclusive license agreement in Greater China for HSP90-PI3K small molecule conjugate drug.
[1] Saisheng Pharmaceutical and Tarveda reached an exclusive license agreement in Greater China for HSP90-PI3K small molecule conjugate drug.
Retrieved Sep 16.
2021.
from https://mp.
weixin.
qq.
com/s/zVKvLYaLEE2z2goz6Q0HBg
